GlassScriptPhysician profile
Jonathan W Necheles
NPI 1518916220
$14,853.65
in general payments reported to CMS, 2019-2025
24 companies · $5,720 in 2025
The $5,720 reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,095 · 2020: $70.62 · 2021: $202 · 2022: $339 · 2023: $689 · 2024: $739 · 2025: $5,720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,770 · Food and Beverage: $2,678 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,770.00 |
| Food and Beverage | $2,677.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia Ab | $6,906.48 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $2,437.56 | 2025 | Neffy |
| Genentech USA, INC. | $1,640.61 | 2025 | Xolair |
| Kaleo, INC. | $864.58 | 2019-2025 | Auvi-Q |
| Pfizer INC. | $609.62 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $595.59 | 2019-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Sanofi Pasteur INC. | $311.84 | 2021-2025 | |
| Seqirus USA INC | $266.70 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Ironshore Pharmaceuticals INC. | $199.23 | 2019-2024 | Jornay Pm |
| Astrazeneca Pharmaceuticals LP | $192.70 | 2022-2025 | |
| Corium, LLC | $145.51 | 2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $134.04 | 2025 | Jornay Pm |
| Sobi, INC | $114.38 | 2019-2023 | |
| Alk-Abello, INC | $81.23 | 2021-2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $65.23 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $57.06 | 2021-2022 | |
| Hologic Sales and Service, LLC | $54.28 | 2021-2025 | Aptima |
| Alexion Pharmaceuticals, INC. | $53.31 | 2024-2025 | Strensiq, Koselugo |
| Kowa Pharmaceuticals America, INC. | $39.20 | 2025 | Zoryve |
| Verrica Pharmaceuticals INC. | $24.44 | 2024 | Ycanth |
| Cranial Technologies, INC | $18.73 | 2023 | Doc Band |
| Noven Therapeutics, LLC | $15.52 | 2024 | Xelstrym |
| Shire North American Group INC | $13.91 | 2019 | |
| Phadia US INC. | $11.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Necheles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.